CTLA4 and neoplasm: The combination of anti-CTLA-4 and anti-PD-1 therapy in mice with high tumor burden (HTB) leads to improved tumor control and to the generation of more activated antigen-specific T cells, as compared to mice with low tumor burden (LTB), in which combination treatment compromised antitumor immune response, inducing the loss of antigen-specific T cells [159].